Matinas biopharma holdings, inc. (MTNB)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Contract research revenue

-

-

-

89

-

-

-

89

29

44

44

44

14

0

0

0

0

0

59

77

57

-

0

-

-

-

-

-

-

Costs and Expenses:
Contract Research Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Research and development

4,086

3,419

2,671

2,828

2,314

1,692

1,379

1,522

2,192

2,298

2,013

2,314

2,384

1,548

835

642

921

1,609

879

1,354

1,448

1,913

1,069

1,118

1,073

726

745

240

49

General and administrative

2,259

2,316

1,889

1,781

1,788

2,474

1,574

1,972

1,957

2,376

1,440

1,706

2,117

1,016

999

977

1,315

1,172

1,339

1,124

1,177

1,396

1,535

1,302

1,055

1,077

708

103

62

Total costs and expenses

6,346

5,735

4,561

4,610

4,103

4,166

2,954

3,494

4,150

4,675

3,453

4,021

4,502

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total costs and expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,835

1,620

2,237

-

2,218

2,478

2,626

3,310

2,605

2,420

2,129

1,803

1,453

343

112

Loss from operations

-6,346

-5,735

-4,561

-4,520

-4,103

-4,166

-2,954

-3,404

-4,120

-4,630

-3,408

-3,976

-4,487

-2,564

-1,835

-1,620

-2,237

-2,782

-2,158

-2,401

-2,568

-3,310

-2,605

-2,420

-2,129

-

-

-

-

Sale of New Jersey net operating loss

1,073

-

-

1,007

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income, net

227

163

156

168

52

33

18

-6

10

8

13

8

-8

-2

-3

-3

-7

19

4

-2

-1

-3

-6

-5

-9

-

-

-

-

Loss from operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,453

-343

-112

Other expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

-

-

Other expense, (income)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net loss

-5,045

-5,572

-4,404

-3,344

-4,050

-3,626

-2,935

-3,411

-4,110

-3,628

-3,394

-3,967

-4,496

-1,891

-1,838

-1,623

-2,244

-2,006

-2,154

-2,404

-2,570

-3,044

-2,611

-2,425

-2,139

-1,801

-1,456

-343

-112

Preferred stock series A accumulated dividends

-

0

45

146

146

146

146

146

147

146

150

152

159

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred stock series B accumulated dividends

170

236

115

115

118

-

175

21

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred stock series B accumulated dividends

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Dividend to preferred shareholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inducement charge from exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Convertible preferred stock beneficial conversion feature accreted as a deemed dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,393

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Inducement charge from exercise of warrants

-

-

-

-

-

-

-

-

-

0

0

0

-16,741

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common shareholders

-5,216

-5,808

-4,564

-3,607

-4,315

-3,893

-3,257

-3,579

-4,257

-3,774

-3,545

-4,120

-21,396

-1,891

-6,232

-1,623

-2,244

-

-2,154

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common shareholders per share - basic and diluted

-0.03

-0.03

-0.03

-0.03

-0.04

-0.03

-0.03

-0.04

-0.05

-0.03

-0.04

-0.04

-0.25

-0.03

-0.11

-0.03

-0.04

-0.03

-0.04

-0.04

-0.07

-0.09

-0.08

-0.08

-0.07

-0.06

-0.10

-0.03

-0.01

Weighted average common shares outstanding:
Basic and diluted

191,671

163,419

156,889

143,104

117,366

110,138

94,697

94,034

93,542

93,470

92,222

91,611

84,595

58,109

57,628

57,593

57,287

57,449

56,970

55,942

35,561

32,246

32,060

32,000

32,000

41,109

14,895

10,000

10,000

Other comprehensive income/(loss), net of tax
Unrealized gain on securities available-for-sale

523

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other comprehensive income/(loss), net of tax

523

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss attributable to shareholders

-4,522

-

-

-

-4,050

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-